Literature DB >> 8108191

Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease.

U Querfeld1, M Lang, J B Friedrich, B Kohl, W Fiehn, K Schärer.   

Abstract

Lipoprotein(a) [Lp(a)] has recently been characterized as a genetically determined risk factor for atherosclerosis and thrombosis. Normally, Lp(a) serum levels are closely related to the apo(a) phenotype. We studied Lp(a) serum levels and apo(a) phenotypes in 136 young subjects, aged 0.8-24.7 y, including patients with glomerular disease and normal renal function (n = 28), patients with chronic renal failure (n = 20), patients treated by hemodialysis (n = 10), peritoneal dialysis (n = 16), and renal transplantation (n = 23), and in controls (n = 39). Of all, 21 patients had proteinuria in the nephrotic range. The distribution of Lp(a) levels in normal subjects was skewed to the left with 97% having levels below 300 mg/L. A subpopulation with increased Lp(a) levels (13-42%) could be detected in all groups with renal disease, and increased mean serum Lp(a) levels were found in patients with nephrotic range proteinuria, in patients with chronic renal failure, and in patients on peritoneal dialysis. Serum Lp(a) levels were not correlated with age, gender, type of renal disease, renal function or severity of proteinuria, but were correlated with the apo(a) phenotype. For a given phenotype, Lp(a) levels tended to be higher in patients than in controls. We conclude that increased Lp(a) serum levels are frequently found in young patients with chronic renal disease, possibly predisposing them to an increased risk for atherosclerosis and thrombosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8108191     DOI: 10.1203/00006450-199312000-00015

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Treatment with growth hormone increases lipoprotein(a) serum levels in children with chronic renal insufficiency.

Authors:  U Querfeld; D Haffner; E Wühl; A M Wingen; K Wolter; B Friedrich; D V Michalk; O Mehls
Journal:  Eur J Pediatr       Date:  1996-10       Impact factor: 3.183

Review 2.  Cardiovascular complications in pediatric end-stage renal disease.

Authors:  Rulan S Parekh; Samuel S Gidding
Journal:  Pediatr Nephrol       Date:  2004-12-15       Impact factor: 3.714

3.  The effect of metabolic acidosis on serum apolipoprotein A I and apolipoprotein B levels in children with chronic renal failure.

Authors:  Z Bircan; A Kaplan; M Soran; M Söker; M Kervancioğlu; A Sahin; M Kilinc
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

4.  Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study.

Authors:  Bryce A Kerlin; Neal B Blatt; Beng Fuh; Shuang Zhao; Amy Lehman; Carol Blanchong; John D Mahan; William E Smoyer
Journal:  J Pediatr       Date:  2009-04-24       Impact factor: 4.406

Review 5.  Lipoprotein metabolism in chronic renal insufficiency.

Authors:  Jeffrey M Saland; Henry N Ginsberg
Journal:  Pediatr Nephrol       Date:  2007-03-28       Impact factor: 3.714

Review 6.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 7.  Disturbances of lipid metabolism in children with chronic renal failure.

Authors:  U Querfeld
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

8.  Carnitine supplementation improves apolipoprotein B levels in pediatric peritoneal dialysis patients.

Authors:  Celalettin Koşan; Lale Sever; Nil Arisoy; Salim Calişkan; Ozgür Kasapçopur
Journal:  Pediatr Nephrol       Date:  2003-10-02       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.